Biotechnological drugs for reproductive disorders: a review of developments.

No abstract is available for this paper.

• Publication year

  1997

• Venue

  BioDrugs

• Publication date

  Unknown publication date

• Fields of study

  Biology, Medicine

• Identifiers
  PMID 18020526
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Recombinant-human luteinizing hormone (r-hLH) as ovulatory stimulus in superovulated does

  2005cited by this paper
• Superovulation before IVF by recombinant versus urinary human FSH (combined with a long GnRH analog protocol): A comparative study

  2005cited by this paper
• Single-dose pharmacokinetics and pharmacodynamics of recombinant human follicle-stimulating hormone (Org 32489*) in gonadotropin-deficient volunteers.

  1998cited by this paper
• Clinical pharmacology of recombinant human follicle-stimulating hormone (FSH). I. Comparative pharmacokinetics with urinary human FSH.

  1998cited by this paper
• Clinical pharmacology of recombinant human follicle-stimulating hormone. III. Pharmacokinetic-pharmacodynamic modeling after repeated subcutaneous administration.

  1998cited by this paper
• Clinical pharmacology of recombinant human follicle-stimulating hormone. II. Single doses and steady state pharmacokinetics.

  1998cited by this paper
• The role of luteinizing hormone in human follicle development and oocyte fertility: evidence from in-vitro fertilization in a woman with long-standing hypogonadotrophic hypogonadism and using recombinant human follicle stimulating hormone.

  1996cited by this paper
• Oestradiol and immunoreactive inhibin-like secretory patterns following controlled ovarian hyperstimulation with urinary (Metrodin) or recombinant follicle stimulating hormone (Puregon).

  1996cited by this paper
• Successful induction ovulation and completed pregnancy using recombinant human luteinizing hormone and follicle stimulating hormone in a woman with Kallmann's syndrome.

  1996cited by this paper
• Follicle stimulating hormone alone supports follicle growth and oocyte development in gonadotrophin-releasing hormone antagonist-treated monkeys.

  1996cited by this paper
• Recombinant follicle stimulating hormone (rFSH; Puregon) in assisted reproduction: more oocytes, more pregnancies. Results from five comparative studies.

  1996cited by this paper
• The regulation of follicle growth: some clinical implications in reproductive endocrinology.

  1996cited by this paper
• Developmental potential of embryos produced by in-vitro fertilization from gonadotrophin-releasing hormone antagonist-treated macaques stimulated with recombinant human follicle stimulating hormone alone or in combination with luteinizing hormone.

  1996cited by this paper
• Genetic engineering of human FSH (Gonal-F).

  1996cited by this paper
• Low‐dose follicle‐stimulating hormone treatment for polycystic ovarian disease

  1996cited by this paper
• Effect of luteinizing hormone on follicle stimulating hormone-activated paracrine signalling in rat ovary.

  1995cited by this paper
• A comparative prospective study of conventional regimen with chronic low-dose administration of follicle-stimulating hormone for anovulation associated with polycystic ovary syndrome.

  1995cited by this paper
• Gonadotropin requirements of the developing follicle.

  1995cited by this paper
• Ovarian stimulation in women undergoing in-vitro fertilization and embryo transfer using recombinant human follicle stimulating hormone (Gonal-F) in non-down-regulated cycles.

  1995cited by this paper
• Pharmacokinetics of recombinant human luteinizing hormone after intravenous, intramuscular, and subcutaneous administration in monkeys and comparison with intravenous administration of pituitary human luteinizing hormone.

  1995cited by this paper
• Efficacy and safety of recombinant follicle stimulating hormone (Puregon) in infertile women pituitary-suppressed with triptorelin undergoing in-vitro fertilization: a prospective, randomized, assessor-blind, multicentre trial.

  1995cited by this paper
• Preserved pituitary response under ovarian stimulation with HMG and GnRH antagonists (Cetrorelix) in women with tubal infertility.

  1995cited by this paper
• Human follicle-stimulating hormone produced by recombinant DNA technology: a review for clinicians.

  1995cited by this paper
• In-vitro biopotency and glycoform distribution of recombinant human follicle stimulating hormone (Org 32489), Metrodin and Metrodin-HP.

  1995cited by this paper
• Gonadotrophin control of follicular function.

  1995cited by this paper
• A prospective, randomized, assessor-blind, multicentre study comparing recombinant and urinary follicle stimulating hormone (Puregon versus Metrodin) in in-vitro fertilization.

  1995cited by this paper
• Recombinant FSH (Org32489) induces follicle growth and ovulation in the adult cyclic rat.

  1995cited by this paper
• Recombinant human luteinising hormone: an effective new gonadotropin preparation.

  1994cited by this paper
• Recombinant human follicle-stimulating hormone stimulates multiple follicular growth, but minimal estrogen production in gonadotropin-releasing hormone antagonist-treated monkeys: examining the role of luteinizing hormone in follicular development and steroidogenesis.

  1994cited by this paper
• Folliculogenesis in hypophysectomized rats after treatment with recombinant human follicle-stimulating hormone.

  1994cited by this paper
• The single or dual administration of the gonadotropin-releasing hormone antagonist Cetrorelix in an in vitro fertilization-embryo transfer program.

  1994cited by this paper
• Low-dose follicle stimulating hormone for ovulation induction in polycystic ovary syndrome.

  1994cited by this paper
• Recombinant human follicle-stimulating hormone and ovarian response in gonadotrophin-deficient women.

  1994cited by this paper
• Simplification of IVF: minimal monitoring and the use of subcutaneous highly purified FSH administration for ovulation induction.

  1994cited by this paper
• First established pregnancy and birth after induction of ovulation with recombinant human follicle-stimulating hormone in polycystic ovary syndrome.

  1994cited by this paper
• Clinical outcome of a pilot efficacy study on recombinant human follicle-stimulating hormone (Org 32489) combined with various gonadotrophin-releasing hormone agonist regimens.

  1994cited by this paper
• Multiple follicular development and ovarian steroidogenesis following subcutaneous administration of a highly purified urinary FSH preparation in pituitary desensitized women undergoing IVF: a multicentre European phase III study.

  1994cited by this paper
• Induction of follicular growth using recombinant human folliclestimulating hormone in two volunteer women with hypogonadotropic hypogonadism

  1994cited by this paper
• Adverse local reaction to intramuscular injections of urinary-derived gonadotrophins.

  1993cited by this paper
• Recombinant human follicle-stimulating hormone treatment leads to normal follicular growth, estradiol secretion, and pregnancy in a World Health Organization group II anovulatory woman.

  1993cited by this paper
• Induction of ovarian follicle luteinization by recombinant follicle-stimulating hormone.

  1993cited by this paper
• Human chorionic gonadotropin or human recombinant follicle-stimulating hormone (FSH)-induced ovulation and subsequent fertilization and early embryo development in hypophysectomized FSH-primed mice.

  1993cited by this paper
• Pure FSH alone induces ovulation and subsequent pregnancy in the mouse resulting in fetal development.

  1993cited by this paper
• Polycystic ovary syndrome: low-dose follicle stimulating hormone administration is a safe stimulation regimen even in previous hyper-responsive patients.

  1992cited by this paper
• The routine use of gonadotropin-releasing hormone agonists prior to in vitro fertilization and gamete intrafallopian transfer: a meta-analysis of randomized controlled trials.

  1992cited by this paper
• Human recombinant follicle-stimulating hormone induces growth of preovulatory follicles without concomitant increase in androgen and estrogen biosynthesis in a woman with isolated gonadotropin deficiency.

  1992cited by this paper
• First singleton term birth after ovarian superovulation with rhFSH.

  1992cited by this paper
• A comparative, randomized study of low-dose human menopausal gonadotropin and follicle-stimulating hormone in women with polycystic ovarian syndrome.

  1991cited by this paper
• Low dose follicle-stimulating hormone therapy for polycystic ovarian disease.

  1991cited by this paper
• Ovulation induction by step-down administration of purified urinary follicle-stimulating hormone in patients with polycystic ovarian syndrome.

  1991cited by this paper
• Low-dose gonadotrophin therapy for induction of ovulation in 100 women with polycystic ovary syndrome.

  1991cited by this paper
• Reevaluation of the roles of luteinizing hormone and follicle-stimulating hormone in the ovulatory process.

  1991cited by this paper
• Comparative in vitro and in vivo studies on the biological characteristics of recombinant human follicle-stimulating hormone.

  1991cited by this paper
• Polycystic ovarian syndrome: safety and effectiveness of stepwise and low-dose administration of purified follicle-stimulating hormone.

  1991cited by this paper
• The control of endogenous secretion of LH by gonadotrophin-releasing hormone agonists during ovarian hyperstimulation for in-vitro fertilization and embryo transfer.

  1990cited by this paper
• Recombinant follicle-stimulating hormone induces ovulation and tissue plasminogen activator expression in hypophysectomized rats.

  1990cited by this paper
• Expression of biologically active human follitropin in Chinese hamster ovary cells.

  1989cited by this paper
• Purified follicle-stimulating hormone in polycystic ovary syndrome: slow administration is safer and more effective.

  1989cited by this paper
• Reproductive/endocrine and anaphylactoid properties of an LHRH-antagonist, ORF 18260 [Ac-DNAL1(2), 4FDPhe2,D-Trp3,D-Arg6]-GnRH.

  1985cited by this paper
• Induction of ovulation with purified urinary follicle-stimulating hormone in patients with polycystic ovarian syndrome.

  1985cited by this paper
• Reduced in‐vitro fertilization of human oocytes from patients with raised basal luteinizing hormone levels during the follicular phase

  1985cited by this paper
• Twin pregnancy after pituitary desensitisation with LHRH agonist and pure FSH.

  1985cited by this paper
• Birth after the reimplantation of a human embryo.

  1978cited by this paper
• Pituitary Control of Ovarian Function — Concepts Derived from Gonadotrophin Therapy

  1978cited by this paper
• Comparisons between the alpha chain of bovine thyrotropin and the CI chain of luteinizing hormone. Compositions of tryptic peptides, cyanogen bromide fragments, and carbohydrate moieties.

  1971cited by this paper
• Clinical effect of human pituitary follicle-stimulating hormone (FSH).

  1958cited by this paper

• Peptide-Coated Nanoparticles for Noninvasive Biomedical Imaging.

  2025cites this paper
• Highly purified hMG versus recombinant FSH plus recombinant LH in intrauterine insemination cycles in women ≥35 years: a RCT.

  2015cites this paper
• Follitropin alpha in infertility: a review.

  1998cites this paper